Browsing by Author "Tatlı, Ali Murat"
Now showing items 1-10 of 10
-
Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: A real-life data of the Turkish Oncology Group
Gürbüz, Mustafa; Kutlu, Yasin; Akkuş, Erman; Köksoy, Elif Berna; Köse, Naziyet; Öven, Bala Başak; Oyan Uluç, Başak; Demiray, Atike Gökçen; Erdem, Dilek; Demir, Bilgin; Turhal, Nazım Serdar; Üskent, Necdet; Akbaş, Sinem; Selçukbiricik, Fatih; İnal, Ali; Bilici, Ahmet; Ölmez, Ömer Fatih; Çabuk, Devrim; Ünal, Çağlar; Hizal, Mutlu; Şendur, Mehmet Ali Nahit; Korkmaz, Mustafa; Karadurmuş, Nuri; Ertürk, İsmail; Göksu, Sema Sezgin; Tatlı, Ali Murat; Güven, Deniz Can; Kılıçkap, Saadettin; Paksoy, Nail; Aydıner, Adnan; Yeşil Çınkır, Havva; Özkul, Özlem; Öztürk, Akın; Ballı, Sevinç; Kemal, Yasemin; Erdoğan, Atike Pınar; Er, Özlem; Yumuk, Perran Fulden; Demirkazık, Ahmet (Springer, 2022)Purpose Atezolizumab has been shown to be effective and safe in randomized trial in the first-line treatment of extensive-stage small cell lung cancer (SCLC). However, there are limited real-life data on atezolizumab. In ... -
Cetuximab-induced rash is associated with overall survival in patients with recurrent/metastatic squamous cell carcinoma of head and neck
Sezgin Göksu, Sema; Tatlı, Ali Murat; Geredeli, Çağlayan; Atçı, Mustafa; Beşen, Ali Ayberk; Mertsoylu, Hüseyin; Uysal, Mükremin; Özdoğan, Mustafa; Göktaş Aydın, Sabin; Bilici, Ahmet; Karaağaç, Mustafa; Artaç, Mehmet; Kaplan, Muhammet Ali; Ebinç, Senar; Coşkun, Hasan Şenol (Springer, 2021)Purpose In this study, we looked for whether treatment-induced rash predicts treatment efficacy in patients with recurrent/metastatic HNSCC treated with Cetuximab and chemotherapy. Methods Patients who were treated with ... -
Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer
İlhan, Yusuf; Tatlı, Ali Murat; Teker, Fatih; Önder, Arif Hakan; Köse, Fatih; Geredeli, Çağlayan; Karaağaç, Mustafa; Kaplan, Muhammet Ali; İnanç, Mevlüde; Göktaş Aydın, Sabin; Kargı, Ayşegül; Arak, Hacı; Özturk, Banu; Beşen, Ali Ayberk; Selvi, Oğuzhan; Korkmaz, Mustafa; Oruç, Zeynep; Bozkurt, Oktay; Bilici, Ahmet; Bayram, Selami; Dae, Shute Ailia; Özdoğan, Mustafa; Coşkun, Hasan Şenol; Sezgin Göksu, Sema (BMJ Publishing Group, 2022)OBJECTIVE: Cisplatin-paclitaxel and bevacizumab is a frequently used treatment regimen for metastatic or recurrent cervical cancer, and carboplatin-paclitaxel and bevacizumab are also among the recommended regimens. In ... -
Comparison of response and survival of first-line crizotinib therapy according to EML-4 ALK fusion variants in advanced non-small cell lung cancer patients: A Turkish Oncology Group study
Tatlı, Ali Murat; Yumuk, Perran Fulden; Öz, Büge; Bilici, Ahmet; Gürsoy, Pınar; Göker, Erdem; Sezer, Ahmet; Özet, Ahmet; Demirci, Umut; Bozkurtlar, Emine; Özbudak, İrem Hicran; Nart, Deniz; Canpolat, Tuğba; Akyürek, Nalan; Kılıçkap, Saadettin (Zerbinis Publications, 2021)Purpose: In the literature there are conflicting data about the treatment efficacy of anaplastic lymphoma kinase (ALK) translocation positive non-small cell lung cancer (NSCLC) patients according to ALK fusion variants. ... -
Crizotinib efficacy and safety in patients with advanced NSCLC harboring MET alterations: A real-life data of Turkish Oncology Group
Gürbüz, Mustafa; Kılıçkap, Saadettin; Bilici, Ahmet; Karadurmuş, Nuri; Sezer, Ahmet; Şendur, Mehmet Ali Nahit; Paydaş, Semra; Artaç, Mehmet; Fulden Yumuk, Perran; Gürsoy, Pınar; Uysal, Mükremin; Şenol Coşkun, Hasan; Tatlı, Ali Murat; Selçukbiricik, Fatih; Dişel, Umut; Köksoy, Elif Berna; Güven, Deniz Can; Uğraklı, Muzaffer; Akkuş, Erman; Yücel, Şebnem; Erol, Cihan; Karakaya, Serdar; Şakalar, Teoman; Khanmammadov, Nijat; Paksoy, Nail; Demirkazık, Ahmet (NLM (Medline), 2022)Crizotinib is a multikinase inhibitor, effective in non-small cell lung cancer (NSCLC) harboring mesenchymal-epidermal transition (MET) alterations. Although small prospective studies showed efficacy and safety of crizotinib ... -
Crizotinib efficacy in alk-positive advanced stage non-small cell lung cancer patients: A real-world experience from Turkey
Kılıçkap, Sadettin; Öztürk, Akın; Karadurmuş, Nuri; Korkmaz, Taner; Yumuk, Perran Fulden; Çiçin, İrfan; Paydaş, Semra; Çılbır, Ebru; Sakalar, Teoman; Uysal, Mükremin; Üskent, Necdet; Demir, Nurcan; Sakin, Ayşegül; Turhal, Nazım Serdar; Keskin, Serhat; Tural, Deniz; Eralp, Yeşim; Buğdaycı Başal, Fatma; Yaşar, Hatime Arzu; Sendur, Mehmet Ali Nahit; Demirci, Umut; Çubukçu, Erdem; Karaağaç, Mustafa; Karaca, Saziye; Tatlı, Ali Murat; Yetişyiğit, Tarkan; Urvay, Semiha; Gürsoy, Pınar; Oyan Uluç, Başak; Turna, Zeynep Hande; Küçüköner, Mehmet; Ölmez, Ömer Fatih; Çabuk, Devrim; Şeker, Mesut; Ünal, Olçun Umut; Meydan, Nezih; Okutur, Sadi Kerem; Tunalı, Duygu (Elsevier Science Inc, 2018)Background: Increasing evidence leads to a ratiocination that genetic heterogeneity of the lung adenocarcinoma patients with sensitive EGFR mutations may impact clinical responses and outcomes to EGFR-TKIs. Method: We ... -
The efficacy and safety of crizotinib in patients with ROS1 positive advanced stage NSCLC: The real-world experience from Turkey
Kılıçkap, Saadettin; Ölmez, Ömer Fatih; Cicin, İrfan; Demirci, Umut; Alan, O.; Çabuk, Devrim; Sakalar, Teoman; Tatlı, Ali Murat; Buğdaycı, F. Başol; Eralp, Yeşim; Uysal, Mükremin; Demirkazik, Ahmet; Bilgin, Burak; Yıldız, Birol; Karaağaç, Mustafa; Okutur, Kerem; Sakin, Ayşegül (Oxford University Press, 2018)… -
Is there any prognostic significance in pleural involvement and/or effusion (Ple-I/E) in patients with ALK-positive NSCLC?
Kılıçkap, Saadettin; Buğdaycı Basal, Fatma; Demirkazık, Ahmet; Gürsoy, Pınar; Demirci, Ufuk; Erman, Mustafa; Yumuk, Fulden; Çay Şenler, Filiz; Çakar, Burcu; Çiçin, İrfan; Öztürk, Akın; Coşkun, Hasan Şenol; Çubukçu, Erdem; Işıkdoğan, Abdurrahman; Ölmez, Ömer Fatih; Tatlı, Ali Murat; Karaağaç, Mehmet Onur; Sakalar, Teoman; Eralp, Yeşim; Korkmaz, Taner (Oxford University Press, 2019)Background: ALK mutation occurs in approximately 3-5% of patients with NSCLC. At the baseline, Ple-I/E are more frequent in ALKþ patients with NSCLC. In the study, we aimed to evaluate characteristics of ALKþpatients who ... -
The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: A Turkish Oncology Group Study
Hızal, Mutlu; Bilgin, Burak; Paksoy, Nail; Açıkgöz, Özgür; Sezer, Ahmet; Gürbüz, Mustafa; Ak, Naziye; Yücel, Şebnem; Ayhan, Murat; Erol, Cihan; Demirkıran, Aykut; Mandel, Nil Molinas; Shbair, Abdallah; Gökmen, İvo; Başoğlu, Tuğba; Paydaş, Semra; Demiray, Atike Gökçen; İriağaç, Yakup; Şakalar, Teoman; Zeynelgil, Esra; Tatlı, Ali Murat; Bahçeci, Aykut; Güven, Deniz Can; Caner, Burcu; Can, Alper; Gülmez, Ahmet; Karakaş, Yusuf; Yalçın, Bülent; Demirkazık, Ahmet; Bilici, Ahmet; Aydıner, Adnan; Yumuk, Perran Fulden; Şendur, Mehmet Ali Nahit (Springer, 2022)Introduction Osimertinib, an irreversible third-generation EGFR-TKI, is the standard of care for second-line treatment of T790M-mutant advanced NSCLC patients whose disease progressed after first-line EGFR-TKI therapy. In ... -
Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: A Turkish Oncology Group study
Hızal, Mutlu; Bilgin, Burak; Paksoy, Nail; Kılıçkap, Sadettin; Atcı, Muhammed Mustafa; Kahraman, Seda; Keskinkılıç, Merve; Bilgetekin, İrem; Ayhan, Murat; Tural, Deniz; Eren, Önder; Akkoç Mustafayev, Fatma Nihan; Yaman, Şebnem; Tatlı, Ali Murat; Bayram, Ertuğrul; Kutlu, Yasin; Ertürk, İsmail; Özcan, Erkan; Gülmez, Ahmet; Korkmaz, Mustafa; Akagündüz, Baran; Erdem, Dilek; Akın Telli, Tuğba; Aksoy, Asude; Üskent, Necdet; İriağaç, Yakup; Köse Baytemür, Naziyet; Aydın, Dinçer; Sakalar, Teoman; Arak, Haci; Selçukbiricik, Fatih; Ergün, Yakup; Korkmaz, Taner; Ak, Naziye; Ünal, Çağlar; Akdeniz, Nadiye; Özgün, Mehmet Alpaslan; Öksüzoğlu, Berna; Yalçın, Bülent; Öztop, İlhan; Algın, Efnan; Sakin, Abdullah; Aydıner, Adnan; Yumuk, Perran Fulden; Şendur, Mehmet Ali Nahit (Future Medicine Ltd., 2022)Aims: In this multicenter study, the authors aimed to determine the real-life efficacy and safety of first-line alectinib. Materials & methods: This retrospective trial included advanced-stage, ALK-positive non-small-cell ...
